Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan D Garely

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
FP Essentials|March 11, 2015
Urogynecologic conditions: urinary incontinenceRobert Kelley, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: pelvic organ prolapseNabila Noor, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: interstitial cystitis/painful bladder syndromeLaurephile Desrosiers, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: chronic pelvic painSalma Rahimi, Alan D Garely
Drug Safety|October 9, 2004
Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adultsAlan D Garely, Lara Burrows
Obstetrics and Gynecology|December 2, 2014
Diagnosis and surgical treatment of stress urinary incontinenceAlan D Garely, Nabila Noor
Expert Opinion on Pharmacotherapy|June 27, 2002
Current pharmacotherapeutic strategies for overactive bladderAlan D Garely, Lara J Burrows
Current Medical Research and Opinion|April 5, 2007
Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomesVeronica Mallett, David Burks, Alan D Garely, et al.
The American Journal of Managed Care|September 16, 2005
Safety and tolerability of tolterodine for the treatment of overactive bladder in adultsRichard G Roberts, Alan D Garely, Tamara Bavendam
The Annals of Pharmacotherapy|March 8, 2007
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomesAlan D Garely, Vincent Lucente, Jonathan Vapnek, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
FP Essentials|March 11, 2015
Urogynecologic conditions: urinary incontinenceRobert Kelley, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: pelvic organ prolapseNabila Noor, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: interstitial cystitis/painful bladder syndromeLaurephile Desrosiers, Alan D Garely
FP Essentials|March 11, 2015
Urogynecologic conditions: chronic pelvic painSalma Rahimi, Alan D Garely
Drug Safety|October 9, 2004
Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adultsAlan D Garely, Lara Burrows
Obstetrics and Gynecology|December 2, 2014
Diagnosis and surgical treatment of stress urinary incontinenceAlan D Garely, Nabila Noor
Expert Opinion on Pharmacotherapy|June 27, 2002
Current pharmacotherapeutic strategies for overactive bladderAlan D Garely, Lara J Burrows
Current Medical Research and Opinion|April 5, 2007
Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomesVeronica Mallett, David Burks, Alan D Garely, et al.
The American Journal of Managed Care|September 16, 2005
Safety and tolerability of tolterodine for the treatment of overactive bladder in adultsRichard G Roberts, Alan D Garely, Tamara Bavendam
The Annals of Pharmacotherapy|March 8, 2007
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomesAlan D Garely, Vincent Lucente, Jonathan Vapnek, et al.
Pageof 2